What’s New in Diabetes Medication

CPD Hours: 1
Current as at 18 February 2021
This presentation will discuss what's new in medications to manage glycaemia for people living with diabetes. Including the new GLP-1 agonists and their use and understand the new evidence for SGLT-2 inhibitors and use this in practice.

“Update your knowledge of new medications used in the management of diabetes”

Course Content

This presentation will discuss what’s new in medications to manage glycaemia for people living with diabetes.

We will discuss new insulins: Ryzodeg, Fiasp, Optisulin and Semglee; confer what biosimilarity signifies in insulins. Dulaglutide and Semaglutide are ground-breaking new GLP-1 therapies to highlight.

We finish with an update on post-market evidence around SGLT-2 inhibitors and its latest member Ertugliflozin.

Learning Outcomes

In this session you will:

  • Update your knowledge of new medications used in the management of diabetes
  • Explore the new insulins Ryzodeg, Fiasp, Optisulin and Semglee
  • Understand the concept of biosimilarity in biological medications such as insulins
  • Become familiar with new GLP-1 agonists and their use and understand the new evidence for SGLT-2 inhibitors and use this in practice
The Nursing CPD Institute

Join NCPDI to access this content.


Join Now

Login if you already have an account.


Login